DT-IL3 Conjugate Selective pDC Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases such as lupus, systemic sclerosis, and psoriasis are inadequate in effectively reducing plasmacytoid dendritic cells (pDCs), which contribute to disease pathology and complications like pulmonary fibrosis and pulmonary arterial hypertension.
Innovation Solution
Administration of a human interleukin-3 (IL-3)-diphtheria toxin conjugate (DT-IL3) to selectively deplete pDCs, reducing their numbers by 20% to 95% without affecting T cells or B cells, thereby mitigating autoimmune disease symptoms and preventing disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current treatments are used for autoimmune diseases, then treatment is provided, but plasmacytoid dendritic cells (pDCs) are not effectively reduced
Solution Approach 1:
The patent extracts and eliminates pDCs from the immune system by using a diphtheria toxin conjugate that specifically targets and kills pDCs. The conjugate binds to the IL-3 receptor on pDC surfaces, delivering the toxin that causes pDC depletion, thereby removing the harmful cell population responsible for autoimmune disease pathology.
Solution Approach 2:
The patent uses an intermediary substance - the diphtheria toxin conjugate - to achieve pDC depletion. This conjugate acts as a mediator between the administered treatment and the target pDCs, binding to their IL-3 receptors and delivering the toxic effect selectively without directly affecting other immune cells.
2Object-affected harmful factors
If pDCs are depleted, then autoimmune disease symptoms are reduced, but disease progression may be affected
Solution Approach 1:
The patent converts the harmful presence of pDCs into a beneficial treatment target. By identifying pDCs as the source of harm (producing type I interferons that drive autoimmune pathology), the treatment strategically depletes these cells to eliminate the harmful effect, thereby converting the disease mechanism into a treatable target.
Solution Approach 2:
The patent employs feedback monitoring through flow cytometry to measure pDC numbers and type I interferon levels before and after treatment. This feedback mechanism allows assessment of treatment effectiveness and adjustment of dosing to ensure sufficient pDC depletion while maintaining safety and preventing excessive immunosuppression.
3Quantity of substance
If DT-IL3 is administered to deplete pDCs, then pDC numbers are reduced by 20-95%, but T cells and B cells may be affected
Solution Approach 1:
The patent achieves local specificity by designing the conjugate to bind exclusively to the IL-3 receptor, which is locally expressed on pDC surfaces but not on T cells or B cells. This local quality distinction in receptor expression enables selective targeting of pDCs while sparring other immune cell types from the toxic effect.
Solution Approach 2:
The patent utilizes parameter changes in receptor expression patterns to achieve selectivity. By exploiting the differential expression of the IL-3 receptor (present on pDCs but absent or low on T and B cells), the treatment creates a parameter-based distinction that guides the conjugate to the correct target population, ensuring high pDC depletion with minimal off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The treatment effectively reduces pDC numbers and type I interferon-inducible gene expression, leading to improved disease scores, reduced skin thickness, and decreased collagen content, effectively managing autoimmune diseases like systemic sclerosis and psoriasis.
Implementation Method 1
a human interleukin-3 (IL-3)-diphtheria toxin conjugate (DT-IL3)... reducing (e.g., depleting, inhibiting, and/or killing) the number of pDCs
Data Source
AI summary
The present disclosure provides, in part, a method of treating an autoimmune disease in a subject by reducing the number of pDCs through administration of a human interleukin-3 (IL-3)-diphtheria toxin conjugate (DT-IL3). The disclosure also generally relates to methods of monitoring the effectiveness of therapy in subjects receiving DT-IL3 for treating an autoimmune disease, and methods of determining continuing treatment of subjects receiving DT-IL3 for treating an autoimmune disease. The disclosure also provides pharmaceutical compositions of DT-IL3 for use in such methods.